Back

Diastolic improvement and left atrial reverse remodelling with mavacamten in obstructive hypertrophic cardiomyopathy: real-world echocardiographic data from China

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Echocardiography in cardiomyopathy: from research to real-world practice Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Wenwen Liang

Zhongshan Hospital Fudan University, Shanghai (China)

4 More presentations in this session

Presentation thumbnail
Echocardiographic assessment of right ventricular hypertrophy and right ventricular-pulmonary artery coupling in hypertrophic cardiomyopathy—implications for outcomes
Mrs A. Clement (Iasi, RO)
Abstract
Presentation thumbnail
Incremental prognostic value of advanced echocardiographic over standard 2D assessment in a real-world clinical population
Doctor G. Benzoni (Milan, IT)
Abstract
Presentation thumbnail
Impact of mitral valvular and subvalvular abnormalities on response to mavacamten in obstructive hypertrophic cardiomyopathy
Mrs M. Herry (Paris, FR)
Abstract
Presentation thumbnail
Cardiac function evaluated with myocardial strain of the four cardiac chambers in adult patients with genetic familial hypercholesterolemia
Doctor L. Soulat-Dufour (Paris, FR)
Abstract

Access the full session

Session thumbnail
Echocardiography in cardiomyopathy: from research to real-world practice

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of mavacamten on left atrial function in hypertrophic obstructive cardiomyopathy
13 December 2024
thumbnail
Congress Presentation
Assessment of cardiac reverse remodeling in patients with LV systolic dysfunction receiving vericiguat in addition to optimal GDMT
13 December 2024
thumbnail
Congress Presentation
Left atrial reservoir strain for diastolic function grading and its associations with long-term outcomes in a community-based cohort
12 December 2024
thumbnail
Congress Presentation
Estimation of the target population of a selective cardiac myosin inhibitor for hypertrophic obstructive cardiomyopathy: Real-life data from the French REMY register.
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources